Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Chen Y, Zhou Q, Hankey W, Fang X, Yuan F. Second generation androgen receptor antagonists and challenges in prostate cancer treatment. Cell Death Dis. 2022;13:632.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mohler ML, Sikdar A, Ponnusamy S, Hwang DJ, He Y, Miller DD, et al. An overview of next-generation androgen receptor-targeted therapeutics in development for the treatment of prostate cancer. Int J Mol Sci. 2021;22:2124.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Posadas EM, Chi KN, de Wit R, de Jonge MJA, Attard G, Friedlander TW, et al. Pharmacokinetics, safety, and antitumor effect of apalutamide with abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: phase Ib study. Clin Cancer Res. 2020;26:3517–24.

Article  CAS  PubMed  Google Scholar 

Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. New Engl J Med. 2019;381:121–31.

Article  CAS  PubMed  Google Scholar 

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352–60.

Article  CAS  PubMed  Google Scholar 

Villa E, Ali ES, Sahu U, Ben-Sahra I. Cancer cells tune the signaling pathways to empower de novo synthesis of nucleotides. Cancers. 2019;11:688.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Löffler M, Fairbanks LD, Zameitat E, Marinaki AM, Simmonds HA. Pyrimidine pathways in health and disease. Trends Mol Med. 2005;11:430–7.

Article  PubMed  Google Scholar 

Evans DR, Guy HI. Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. J Biol Chem. 2004;279:33035–8.

Article  CAS  PubMed  Google Scholar 

Scherer S, Oberle SG, Kanev K, Gerullis AK, Wu M, de Almeida GP, et al. Pyrimidine de novo synthesis inhibition selectively blocks effector but not memory T cell development. Nat Immunol. 2023;24:501–15.

Article  CAS  PubMed  Google Scholar 

Madak JT, Bankhead A 3rd, Cuthbertson CR, Showalter HD, Neamati N. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer. Pharmacol Ther. 2019;195:111–31.

Article  CAS  PubMed  Google Scholar 

Robinson AD, Eich ML, Varambally S. Dysregulation of de novo nucleotide biosynthetic pathway enzymes in cancer and targeting opportunities. Cancer Lett. 2020;470:134–40.

Article  CAS  PubMed  Google Scholar 

Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383:546–57.

Article  CAS  PubMed  Google Scholar 

Zeng F, Li S, Yang G, Luo Y, Qi T, Liang Y, et al. Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis. Acta Pharm Sin B. 2020;11:795–809.

Article  PubMed  PubMed Central  Google Scholar 

Zhou J, Yiying Quah J, Ng Y, Chooi JY, Hui-Min Toh S, Lin B, et al. ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia. Haematologica. 2020;105:2286–97.

Article  CAS  PubMed  Google Scholar 

Zhou Y, Tao L, Zhou X, Zuo Z, Gong J, Liu X, et al. DHODH and cancer: promising prospects to be explored. Cancer Metab. 2021;9:22.

Article  PubMed  PubMed Central  Google Scholar 

Mao C, Liu X, Zhang Y, Lei G, Yan Y, Lee H, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature. 2021;593:586–90.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Pal S, Kaplan JP, Nguyen H, Stopka SA, Savani MR, Regan MS, et al. A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma. Cancer Cell. 2022;40:957–972.e910.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gwynne WD, Suk Y, Custers S, Mikolajewicz N, Chan JK, Zador Z, et al. Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma. Cancer Cell. 2022;40:1488–1502.e1487.

Article  CAS  PubMed  Google Scholar 

Christian S, Merz C, Evans L, Gradl S, Seidel H, Friberg A, et al. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. Leukemia. 2019;33:2403–15.

Article  CAS  PubMed  Google Scholar 

Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008;68:6407–15.

Article  CAS  PubMed  Google Scholar 

Zhao J, Ning S, Lou W, Yang JC, Armstrong CM, Lombard AP, et al. Cross-resistance among next-generation antiandrogen drugs through the AKR1C3/AR-V7 axis in advanced prostate cancer. Mol Cancer Ther. 2020;19:1708–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK, et al. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res. 2012;72:6142–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang JC, Xu P, Ning S, Wasielewski LJ, Adomat H, Hwang SH, et al. Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene. 2023;42:693–707.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mostaghel EA, Marck BT, Kolokythas O, Chew F, Yu EY, Schweizer MT, et al. Circulating and intratumoral adrenal androgens correlate with response to abiraterone in men with castration-resistant prostate cancer. Clin Cancer Res. 2021;27:6001–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lorente D, Llacer C, Lozano R, de Velasco G, Romero-Laorden N, Rodrigo M, et al. Prognostic score and benefit from abiraterone in first-line metastatic, castration-resistant prostate cancer. Eur Urol. 2021;80:641–9.

Article  PubMed  Google Scholar 

Mei Z, Yang T, Liu Y, Gao Y, Hou Z, Zhuang Q, et al. Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment. Cell Rep Med. 2022;3:100608.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Swami U, McFarland TR, Nussenzveig R, Agarwal N. Advanced prostate cancer: treatment advances and future directions. Trends Cancer. 2020;6:702–15.

Article  CAS  PubMed  Google Scholar 

Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70:479–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, et al. Management of patients with advanced prostate cancer: report from the advanced prostate cancer consensus conference 2021. Eur Urol. 2022;82:115–41.

Article  CAS  PubMed  Google Scholar 

Dellis AE, Papatsoris AG. Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer. Expert Opin Investig Drugs. 2018;27:553–9.

Article  CAS  PubMed  Google Scholar 

Shore N, Zurth C, Fricke R, Gieschen H, Graudenz K, Koskinen M, et al. Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial. Target Oncol. 2019;14:527–39.

Article  PubMed  PubMed Central  Google Scholar 

Diehl FF, Miettinen TP, Elbashir R, Nabel CS, Darnell AM, Do BT, et al. Nucleotide imbalance decouples cell growth from cell proliferation. Nat Cell Biol. 2022;24:1252–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang C, Zhao Y, Wang L, Guo Z, Ma L, Yang R, et al. De novo pyrimidine biosynthetic complexes support cancer cell proliferation and ferroptosis defence. Nat Cell Biol. 2023;25:836–47.

Article  CAS  PubMed